CURE interviewed Eileen O’Reilly, M.D. about the SHARON clinical trial and data presented at the recent European Society for Medical Oncology (ESMO) conference. Dr. O’Reilly discusses the scientific rationale for the study, the patient population under investigation, and the early observations that motivated continued clinical evaluation of the approach.
Dr. O’Reilly states: “The SHARON study is a very interesting, unique trial that, to date, has been focused on individuals with pancreas cancer and breast and a couple of other malignancies who have a germline BRCA1, BRCA2 or PALB2 mutation.”
Additionally, Dr. O’Reilly shares her perspective on the preliminary data generated in the study.
Read the full interview at: https://www.curetoday.com/view/sharon-trial-offers-a-potential-approach-for-advanced-pancreatic-cancer